Table 1.
Although a relatively small body of comparative work, it can be seen that across all classes of compounds in which there have been studies in pet animal chronic pain conditions (osteoarthritis, osteosarcoma) and the same condition in humans, the same conclusions have been observed, but not always agreeing with the body of work in rodents.
| Drug | Efficacy in rodents | Efficacy in dogs | Efficacy in humans | References |
|---|---|---|---|---|
| NSAIDs | Yes | Yes | Yes | (15, 18) |
| Anti-NGF mAbs | Yes | Yes | Yesa | (12, 13) |
| TRPV1 antagonist | Yes | No | No | (16, 19) |
| Resiniferatoxin | Yes | Yes | Yes | (17, 20, 21) |
| Substance P-saporin | Yes | Yes | (Awaiting results) | (22, 23) |
| NSAID EP4 receptor antagonist | Yes | Yes | (Ongoing) | (24, 25) |
| Capsaicin (intra-articular) | Yes | Yes | (26) |
This table is a high overview of the predictive utility.
a
The first anti-NGF mAb for humans has recently been declined a marketing authorization by the FDA on the basis of only modest efficacy and side-effects; in contrast, anti-NGF mAb products are now approved for use in dogs and cats in several countries across the globe.